On the Mark: Identifying Non-Invasive Biomarkers of Target Engagement

A key aspect of the drug discovery pipeline is evaluation of in vivo target engagement and subsequent biological response. Direct measures of tissue target engagement are often limited in human subjects as part of early clinical studies, and therefore circulating small molecule biomarkers in blood may serve as a robust means for measure of target engagement by providing a non-invasive approach for understanding drug dosing, tissue penetration, target engagement, and therapeutic response.
In this session, Dr. Mohit Jain, Founder and CEO of Sapient, discusses methods for the rapid discovery of small molecule biomarkers of target engagement, leveraging integration of next generation mass spectrometry, genomics, and experimental systems.